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ABSTRACT
Genomic characterization of medulloblastoma has improved molecular risk
classification but struggles to define functional biological processes, particularly for
the most aggressive subgroups. We present here a novel proteomic approach to this
problem using a reference library of stable isotope labeled medulloblastoma-specific
proteins as a spike-in standard for accurate quantification of the tumor proteome.
Utilizing high-resolution mass spectrometry, we quantified the tumor proteome of
group 3 medulloblastoma cells and demonstrate that high-risk MYC amplified tumors
can be segregated based on protein expression patterns. We cross-validated the
differentially expressed protein candidates using an independent transcriptomic
data set and further confirmed them in a separate cohort of medulloblastoma tissue
samples to identify the most robust proteogenomic differences. Interestingly, highly
expressed proteins associated with MYC-amplified tumors were significantly related
to glycolytic metabolic pathways via alternative splicing of pyruvate kinase (PKM) by
heterogeneous ribonucleoproteins (HNRNPs). Furthermore, when maintained under
hypoxic conditions, these MYC-amplified tumors demonstrated increased viability
compared to non-amplified tumors within the same subgroup. Taken together, these
findings highlight the power of proteomics as an integrative platform to help prioritize
genetic and molecular drivers of cancer biology and behavior.

INTRODUCTION

at least four distinct subgroups with significantly different
clinical outcomes and therefore warranting individual
therapeutic consideration [1]. Group 3 MB has the worst
outcome with independent studies reporting between
40 to 50% overall survival [1-3]. Metastases and myc
amplification predict poor prognosis in Group 3 MB
despite aggressive therapy [4]. As a result, there is an

Remarkable progress has been made in defining the
genomic aberrations that underlie pediatric brain tumors.
In regard to medulloblastoma (MB), the most common
malignant pediatric brain tumor, what was originally
perceived to be a single entity is now known to consist of
www.impactjournals.com/oncotarget
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RESULTS

imperative to improve therapy for patients with group 3
tumors, with a particular focus on high risk cases [5].
Although transcript-based profiling technologies
enable separation of subgroups based on gene expression,
it is often difficult to interpret such signatures with respect
to the biology of the disease. This is largely because
these gene signatures do not incorporate important
functions downstream of gene transcription, including
splice isoform switching, selective translation and posttranslational modification [6]. Proteomics provides a
unique complementary platform to precisely characterize
altered signal transduction in cancer cells, examine cellular
processes and identify potential therapeutic targets. Recent
advances in mass spectrometry (MS) technology have
improved protein identification and quantitation due to
increased sensitivity, accuracy and speed of analysis [7-9].
The stable-isotope labeling of amino acids in cell culture
(SILAC) method is a particularly accurate quantitative
technique that has recently been used to identify diffuse
large B-cell lymphoma subtypes and quantify diverse
human tumor proteomes [6, 10].
SILAC involves incorporating amino acids
constructed using the isotopes 13C and/or 15N into proteins.
This increase in mass allows otherwise chemically
indistinguishable peptides from different samples to
be individually quantified by the mass spectrometer,
even when pooled. Specifically, a protein lysate from
an experimental sample can be pooled with a known
quantity of an isotope-labeled protein lysate, fractionated
and digested into peptides. The mass spectrometer
can then quantitate both the naturally occurring 12Cand 14N-containing as well as the heavy analytes as a
ratio. Performing this process iteratively with multiple
experimental samples is a proven method for relative
quantification of peptides, and thus proteins, between
those samples [12].
We present here the first in depth proteomic
profiling of MB using multiple SILAC labeled cell
lines as an internal standard for agnostic tumor protein
quantification. We specifically investigate proteins with
differential abundance between low (non-MYC amplified)
and high risk (MYC amplified) group 3 MB tumors [11],
and identify targets that provide insight into the tumor
biology of this aggressive subgroup. In summary, our data
demonstrates the potential of SILAC-based proteomics
to reliably quantify global proteome differences and
to complement the current understanding of genomic
abnormalities in medulloblastoma.

www.impactjournals.com/oncotarget

Super-SILAC proteomic analysis enables accurate
quantification of subgroup specific proteins
Current antibody based proteomic techniques are
useful tools, but only once a small set of target proteins
have been identified. Mass spectrometry, by contrast,
provides broad proteome coverage, but has historically
been plagued by low sensitivity, inaccurate quantitation
and technical variability. For this study, we utilized a
novel SILAC based mass spectrometry technique to
reproducibly quantify proteome differences in human
primary tumor cells. The SILAC approach involves the
use of a set of stable isotope-labeled labeled peptides
that can be spiked, at known amounts, into test samples
and used as an internal reference standard for accurate
quantification of proteins by mass spectrometry [12]. We
developed a unique SILAC reference standard comprised
of three labeled MB tumor cell lines (DAOY, D556,
D283) and a labeled low passage primary MB tumor cell
culture (R026; group 3 non-metastatic tumor) (Figure 1A).
This mixture is termed super-SILAC as it is a superset
of SILAC cell lines and has previously been shown to
achieve superior quantification accuracy compared to
single SILAC-labeled cell line standards [10]. Creating
the reference from a pool of labeled protein lysates from
multiple MB primary and established cell lines broadens
proteome coverage to increase the number of quantifiable
proteins in the experimental MB samples.
To test the proteomic coverage and accuracy
of our unique super-SILAC standard when studying
heterogeneous subsets of MB, we evaluated primary
lines representing the 4 molecular subgroups of MB. We
identified between 1400-1900 proteins per primary MB
cell line; ≥94.5% of all peptides fell within a 2.5-fold ratio
of tumor to SILAC standard (Figure 1B). This narrow
ratio distribution contributed to significantly higher
quantification accuracy with all MB cells displaying
a ≥0.92 Pearson correlation coefficient of variation
between triplicate analyses (Figure 1B). Approximately
half of all proteins identified (45-56%), using stringent
peptide probability scores and false discovery rate filters
(see Methods and materials), were shared by all MB
subgroups, with Group 3 and Group 4 displaying the
greatest similarity in their proteomes (Figure S1). There
was no significant difference in quantification accuracy
and proteome coverage across the MB subgroups ( > 80%
of proteins overlapped between the standard and each
sample; Figure S1), demonstrating the ability of our superSILAC standard to function across diverse subgroups of
MB. In summary, our unique MB super-SILAC standard,
together with high-resolution mass spectrometry, was
able to accurately and reproducibly quantify a large
2
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Figure 1: Effective quantification of human primary tumor cells using a super-SILAC reference standard. A.

Experimental scheme of quantification analysis using mixed lysates of multiple MB tumor cell lines. Lysates of labeled cells (Lys-8, 13C6
15
N2-Lysine; Arg-10, 13C6 15N4-Arginine) are mixed with tumor lysate (at a 1:1 ratio) and analyzed by high resolution liquid chromatographyMS/MS. B; Histograms of the ratios between the tumor protein and our super-SILAC reference, and a comparison of ratios (r = Pearson
correlation coefficient) between replicates demonstrates the high quantification accuracy of our technique. Superior accuracy is achieved
when quantified proteins (proportion indicated by percentage above histogram) lie within four-fold ratio between tumor and super-SILAC
reference [10]
www.impactjournals.com/oncotarget
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set of proteins across all MB tumor subgroups. Having
illustrated the effectiveness of our super-SILAC standard,
we next evaluated the proteomic differences between
MYC amplified versus non-amplified tumors.

actionable targets. MYC amplification in this subtype is
significantly associated with metastasis and poor survival,
yet little is known regarding the cellular and molecular
mechanisms that produce this aggressive phenotype.
Using our super-SILAC standard we explored the global
proteome differences between human MYC amplified
(MYC+, n = 3) versus non-MYC amplified (MYC-, n = 3)
Group 3 primary tumor cells. Interestingly, unsupervised
hierarchical clustering of the median protein expression
values of all quantified proteins resulted in segregation
by MYC amplification status (Figure 2A-2B). Focusing

Differential proteome patterns in MYC amplified
versus non-MYC amplified Group 3 tumor cells
Group 3 MB has the worst overall survival ( < 50%)
and transcriptional profiling analyses have not revealed

Figure 2: Differential proteome expression patterns between MYC-amplified versus non-amplified tumors. A.

Unsupervised hierarchical clustering (normalized log2 and standardized to mean signal = 0 and standard deviation = 1) of protein expression
profiles from six Group 3 primary MB cells B. Differential protein expression drives segregation of tumor cells with MYC-amplification,
which is not seen when similar analysis is conducted using transcriptome data (see FigS3). B, C. Top up-regulated proteins and predicted
functional pathways in MYC-amplified tumors. STRING-generated protein-protein interaction pathways revealed significant (P, 0.05;
t-test) connectivity in alternative splicing, ribosome biogenesis and metabolism pathways. Error bars represent standard deviation between
the cultures in each subgroup (n = 6)
www.impactjournals.com/oncotarget
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on only significant protein changes (p-value with FDR
correction < 0.001), we identified 185 proteins (Table
S1) that were differentially expressed between MYC
amplified and non-amplified tumors (Figure 2C; Table S1).
Intriguingly, some of the highest differentially expressed
proteins, such as orthodenticle homeobox 2 (OTX2) and
DEAH box helicase 9 (DHX9), have previously been
shown in genomic studies to be strongly associated

with Grp3/4 MB [1, 2, 12]. To determine the functional
significance of these proteins, we utilized the Search Tool
for the Retrieval of INteracting Genes/Proteins (STRING)
database of physical and functional interactions [13]. In
the global STRING-generated protein-protein network,
several complexes and cellular functions formed prominent
tightly connected clusters (Figure S2). Cellular processes
such as RNA splicing and cellular metabolism were

Figure 3: Validation of differential protein expression in independent human MB tissue samples and evidence for
increased alternative splicing of PKM. A. Confirmation of proteomic alterations in independent human MB tissue samples using
western blot. Significant (t-test) alterations in splicing associated factors were conserved between low passage primary tumor cell cultures
and human tissue samples. B. Quantitative real-time PCR in human MB tissue and cell cultures reveals increased alternative splicing of
PKM to produce the pro-glycolytic PKM2 isoform in MYC amplified tumors. C. cDNA samples from independent human tissue samples
were subjected to PCR amplification using primers amplifying a 442 bp exon 8-11 region common to PKM1 and PKM2. Following
incubation with PstI, the uncleaved (PKM1, 442 bp) and cleaved (PKM2, 246 and 196 bp) amplification products were separated by
electrophoresis and quantified, with total signal set at 100 for each lane (Lane 1 uncut MYC-, Lane 2 uncut MYC+). There is significantly
higher splicing of mRNA which is indicative of higher PKM2 isoforms.
www.impactjournals.com/oncotarget
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particularly enriched in MYC+ tumors compared to MYC(Figure 2D). These MYC+ associated cellular pathways
prominently featured heterogeneous ribonucleoproteins
(HNRNPAB, HNRNPH1, and HNRNPC) and serine/
arginine-rich splicing factors (SRSF2, SRSF7), indicative
of post-transcriptional modification pathways. We further
validated our proteomic data by western blot analysis,
confirming the significantly differential expression of
spliceosome associated proteins (Figure S3). Western blot
analysis of Grp3 tumor cell lines was consistent with our
super-SILAC mass spectrometry observations.
To determine the relationship between our
proteomic findings and the transcriptomic landscape, we
performed an orthogonal analysis of independent gene
expression data from the largest single human MB study
(GEO accession number GSE37385) [14] to determine
the differential gene expression between ten MYC+ and
ten MYC- human Grp3 MB tumors. There was limited
concordance between protein and mRNA variation (8%
similarity with differentially expressed gene transcripts
with p < 0.05). Interestingly, interaction pathways
generated from these common proteogenomic targets
revealed strikingly similar pathways to those seen in our
proteomic data alone (Figure S3;. These results highlight
the strength of proteomics to help validate and prioritize
the broad output of genomic studies to determine those
most closely associated with cancer function/biology.

glycolysis, whereas the adult isoform, PKM1, promotes
oxidative phosphorylation. These two isoforms result
from mutually exclusive alternative splicing of PKM premRNA leading to the inclusion of either exon 9 (PKM1)
or exon 10 (PKM2). We therefore used quantitative PCR
analysis using primers specific for PKM exon 9 or PKM
exon 10 to determine shifts in the PKM2/PKM1 ratio.
Real time PCR (RT-PCR) revealed increased levels of
the PKM2 isoform in the MYC+ MB tumors compared to
MYC- tumors, and a subsequently higher PKM2/PKM1
ratio (Figure 3B). Although there was high variability in
the PKM2/PKM1 ratios among the MYC+ tumor tissues,
the mean ratio was significantly higher (P = 0.016, MannWhitney test) than in the non-amplified MYC tumors. This
was further confirmed in a partially overlapping human
MB tumor tissue set using a restriction enzyme assay to
assess the proportion of PKM1 and PKM2 (Figure 3C; P
= 0.012, t test).

Alterations in glycolytic metabolism in MYC
amplified MB tumor cells
Alternative splicing of PKM plays an important role
in determining the metabolic phenotype of mammalian
cells. We set out to determine if the increased splicing
factors and subsequent alternative splicing of PKM,
resulting in a high PKM2/PKM1 ratio, correlated with
glycolytic metabolism in these tumor cells. Intriguingly,
MYC amplified tumor cells displayed a significantly
higher production of total oxidized and reduced
nicotinamide adenine dinucleotide phosphates (NADP+
and NADPH, respectively) when compared to nonamplified (MYC-) cells (P < 0.01; Figure 4A). High
metabolic flux through glycolysis produces ATP and
intermediates which subsequently generate NADPH and
ribose for reductive biosynthetic reactions and nucleotide
synthesis - both critical to a highly proliferative phenotype.
Surprisingly, although increased reactive oxidative species
(ROS) production is associated with up-regulation of
glycolysis, we saw significantly lower levels of H202 in our
MYC-amplified tumor cells (P < 0.01; Figure 4A). This
ROS quantification was independent of cell survival and
proliferation, as determined by cell viability assays after
ROS measurements (Figure S4). As we also demonstrate
significantly higher protein expression of superoxide
dismutase (SODm) in MYC+ tumors (see Table S1), these
results may suggest an adaptation to a phenotype resistant
to acid-induced toxicity. Constitutive up-regulation of
glycolysis is proposed to be an adaptation to hypoxia. To
test this, we compared ATP production in cultures grown
under hypoxic ( < 1% O2) and normoxic conditions. All
non-amplified MYC cultures, except for the DAOY cell
line, produced significantly (P < 0.05) lower ATP when
grown in hypoxic conditions (Figure 4B). Conversely,
there were no significant differences in ATP production in

Cross-validation of proteomic MYC-signature in
independent human tumor tissue samples
Proteomic differences in our primary tumor cultures
could result from adaptations to an in vitro culturing
system and may not faithfully reflect protein expression
in human tumor tissues. To validate proteomic differences
shown in our super-SILAC system, we used western
blotting on an independent group of human tumor tissue
samples (n = 10; see Table S2). Greater proteomic
variability was observed between human tumor tissue
samples than in culture, however significant differences
in HNRNPA2/B1 (p = 0.005) and MYC (p = 0.013) were
still detected between MYC+ and MYC- tissues (Figure
3A). There were no significant differences in HNRNPA1
(p = 0.068) and HNRNPC (p = 0.281), which were
significantly higher in MYC+ primary cultures compared
to MYC-. These results support our in vitro finding of
altered expression of splicing factors in MYC+ group 3
human MB tissues.
We next determined whether this significant increase
in splicing factors was associated with increased splicing
of their targets. Notably, HNRPNPA1, HNRPNPA2 and
PTB have previously been shown to regulate alternative
splicing of pyruvate kinase pre-mRNA (PKM) resulting in
increased levels of the embryonic pyruvate kinase isoform,
PKM2 [15]. Importantly, PKM2 promotes aerobic
www.impactjournals.com/oncotarget
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MYC+ cells grown in a hypoxic environment, except for
the D556 cell line, when compared to normoxia (Figure
4B). In summary, energy production was unperturbed

in primary MYC+ MBs when cultured under hypoxic
conditions.

Figure 4: MYC-amplified tumor cells have significantly altered metabolic activity compared to the rest of Group 3 MB
cells (non-MYC amplified). A. Although MYC amplified tumor cells have significantly lower reactive oxidative species (H2O2), they

also have higher levels of total nicotinamide adenine dinucleotide phosphates (t-test; p < 0.01; error bars are standard deviation between
subgroup cultures). B. ATP production under hypoxic conditions (48 hours, 0.1% O2) is significantly reduced in most (3/4) non-MYC
amplified tumor cells, but is not perturbed in MYC-amplified tumors (3/4). Error bars are standard deviation of sample replicates; t-test,*
denotes P < 0.05.
www.impactjournals.com/oncotarget
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significant differences in protein expression between
MYC-amplified and non-amplified tumors, though
whether this is directly related to increased MYC
transcript expression is an open question. For example,
two of the primary MYC amplified lines used to generate
the proteomic data also harbor OTX2 amplifications. As
OTX2 amplification is known to cooperate with MYC
to amplify its transcriptional program, and OTX2 was
the most differentially expressed protein found in the
MYC+ group, it is possible that the proteomic phenotype
here described is driven by the cooperation of these two
oncogenes [22].
MYC amplification is more closely associated with
group 3 MBs than any other group and makes an excellent
prognostic marker in combination with established clinical
risk factors [11]. However, transcriptional profiling
has not revealed appreciable myc-dependent signaling
pathways [2, 12] and next-generation sequencing in three
independent studies yielded few recurrent mutations in this
group [3, 23-25]. The proteomics perspective enhances
and complements our current understanding of genomic
drivers of cancer biology and provides a novel platform
for exploring molecular pathways in medulloblastoma.

The results of this study demonstrate the power
of quantitative proteomics as a platform to help discern
molecular and genetic drivers of cancer. The application of
proteomics is particularly useful when studying genetically
ambiguous tumors like group 3 MB, which has the highest
levels of recurrence and the worst overall survival rates
[1, 3, 12]. Our proteomic findings, validated in clinical
samples at the level of transcript and protein, provide new
evidence of the biological effect of MYC amplification
in group 3 MB. Specifically, we demonstrate alternative
splicing of pyruvate kinase mRNA by HNRNPs and the
subsequent altered metabolic phenotype in these tumors.
Intriguingly, this may influence the bioenergetics of MYC
amplified tumors and therefore confer a powerful growth
advantage necessary for the evolution and metastasis of
this aggressive cancer.
Our proteomics data highlight significant differences
in the metabolism of MYC amplified versus non-amplified
tumors. This pathway has not previously been studied in
MB, possibly due to the hypothesis that MYC amplification
was primarily associated with dysregulated cellular
proliferation with a subsequent increase in metabolism.
However, previous findings that MYC directly regulates
genes involved in glucose metabolism and ribosome
biogenesis (also supported in this study), suggests that the
increased production of metabolic enzymes in growing
cells is far from a passive phenomenon [16-19]. Enhanced
metabolic capacity is essential for biomass accumulation
and high-fidelity DNA replication in a growing cell. This
enhanced capacity requires rewiring of the metabolic
energetics of a resting cell into that of a growing and
proliferating cell. To this effect, MYC stimulates virtually
all of the genes involved in glycolysis [15, 20]. High
metabolic flux through glycolysis provides growing cells
with the building blocks for macromolecular synthesis
and ATP production. Importantly, our results suggest that
this shift in metabolism in MYC amplified tumors may
likely influence the adaptation of these cells to a hypoxic
microenvironment. This is supported by evidence that
MYC induction of glutamine metabolism is important
for cell survival under glucose and oxygen-deprived
conditions [18, 20]. Taken together, we propose that this
MYC-amplification associated glycolytic phenotype may
confer a powerful growth advantage and influence the
aggressive behavior of this tumor subtype.
It is important to note that myc amplification in
this context defines a subgroup of tumors whose biology
is not necessarily wholly defined by the transcriptional
activity of MYC and its target genes. This is an important
distinction that has been written about previously [21].
In fact, increased MYC expression (without MYC copy
number variation) is also found in the WNT subgroup
medulloblastoma tumors with the highest survival. The
data presented here support the concept that there are
www.impactjournals.com/oncotarget

MATERIALS AND METHODS
Patients and samples
The use of human tissue (Table S2) was approved
by the institutional review board of Children’s National
Medical Center (Washington DC, USA) (IRB 4932).
Written informed consent was obtained at the time of
surgical resection. De-identified MB tissue were obtained
from Queensland Children’s Tumor Bank (Brisbane,
Australia), German Cancer Research Center (Heidleberg ,
Germany), Sanford-Burnham Medical Research Institute
(La Jolla, USA), and Hospital for Sick Children (Toronto,
Canada). Primary passage patient derived mouse xenograft
cells were provided by Dr. Wechsler-Reya (SanfordBurnham Medical Research Institute, La Jolla, USA).

Cell lines and SILAC culture
Primary MB cell cultures R001, R026, R032, R060,
and R066 (see Table S2 for details) were obtained from
Queensland Children’s Tumor Bank. The cell lines were
cultured in ‘light’ DMEM: F12 media (Gibco) containing
naturally occurring lysine and arginine and supplemented
with 10% fetal bovine serum (Gibco), 1% glutamax
(Gibco), 1% sodium pyruvate (Life Technologies, Grand
Island, NY) and 1% penicillin/streptomycin/fungizone
(supplier). MB002 and MB004 cell cultures were a kind
gift from Dr. Jae Cho (Stanford University, Stanford,
CA) and maintained in 1:1 DMEM/F12 (Gibco) and
8
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Neurobasal-A medium (Gibco) supplemented with
B27 (Gibco), EGF (Fisher Scientific), fibroblast growth
factor (Fisher Scientific), Heparin (Sigma-Aldrich), and
leukemia inhibitory factor (Millipore). Established MB
cell lines D556 and D283 were generously provided by
Dr. Darrell Bigner (Duke University, Durham, NC) and
the DAOY cell line obtained from the American Type
Tissue Collection. These cell lines were SILAC-labeled
by culturing in DMEM media (Life Technologies,
Grand Island, NY) containing ‘heavy’ isotope-labeled
essential amino acids, 13C6 ,15N2-lysine (Lys-8) and
13
C6, 15N4-arginine (Arg-10 ). The labeled amino acids
were purchased from Cambridge isotope Laboratories
(Andover, MA). Media was supplemented with 10% fetal
bovine serum, 1% glutamax, 1% sodium pyruvate and
1% antibiotics as above. The primary cell line R026 was
also SILAC labeled by culturing in DMEM:F12 media
(Thermoscientific, Rockford, IL) where Lys-8 and Arg10 replaced naturally occurring amino acids. Cell lines
were cultured for at least 6 population doublings until
fully labeled, as confirmed by mass spectrometry ( >
99% incorporation, data not shown). All cell lines were
maintained at 37°C and 5% CO2. It is important to note
that of the cell lines used in our super-SILAC mix, D283
and D556 harbor cMYC gene copy number amplifications
whereas DAOY and R026 do not.
Cell pellets from all unlabeled cell lines and SILAClabeled cell lines and snap frozen tumor tissue were lysed
in RIPA buffer (Millipore, Temecula, CA) containing
2% SDS (Lonza, Rockland, ME) and protease inhibitors
(Thermoscientific, Rockford, IL). Lysates were incubated
on a shaker at 4°C for 30 minutes and sonicated for 10
minutes followed by centrifugation. Snap frozen tumor
tissue was homogenized with a handheld homogenizer
then lysed using the same method. The supernatant was
reserved and protein concentration was determined by
BCA assay (Pierce Thermoscientific, Rockford, IL) at a
wavelength of 562nm. The super-SILAC spike-in standard
was created by mixing equal amounts of protein from
each SILAC-labeled cell line (R026, DAOY, D556 and
D283). Protein concentration was determined by BCA
assay and aliquots of the standard were stored at -80°C
until required.

95°C for five minutes. Proteins were resolved by SDSPAGE on Criterion XT 4-12% Bis-Tris gels (Bio-Rad,
Hercules, CA) at 180 volts for 1 hour. The gels were
fixed (50:5:45/methanol:aceticacid:water/v:v:v), stained
with Bio-Safe Coomassie blue (Bio-Rad, Hercules, CA)
and destained in H2O. 32 gel sections were excised from
each sample run and the individual bands were processed
for in-gel trypsin proteolysis as previously described10.
Trypsin digestion was performed using 12.5ng/ul of mass
spectrometry grade Trypsin (Promega, Madison, WI)
diluted in 25mM NH4HCO3 solution. Peptides recovered
from each band were dried by vacuum centrifugation and
resuspended in 8ul of 0.1% TFA for mass spectrometry
analysis.

Mass spectrometry analysis
NanoLC MS and MS/MS were conducted using
the Eksigent nanoLC 2D HPLC system (Eksigent
Technologies, Inc., Dublin, CA) coupled to the LTQOrbitrap XL hybrid mass spectrometer (Thermo Fisher
Scientific, San Jose, CA). Peptides from each band were
injected via an autosampler (6uL) and loaded onto a
Symmetry C18 trap column (5µm, 300 µm i.d. x 23 mm,
Waters) for 10 min at a flow rate of 10 µL/min, water with
0.1% formic acid. The sample was subsequently separated
by a C18 reverse-phase column (3 m, 200A, 100 µm x 15
cm, Magic C18, Michrom Bioresources) at a flow rate of
300 nL/min using an Eksigent nano-hplc system (Dublin,
CA). The mobile phases consisted of water with 0.1%
formic acid (A) and 90% acetonitrile (B). A 65 minute
linear gradient from 5 to 60% B was employed. Eluted
peptides were introduced into the mass spectrometer via
Michrom Bioresources CaptiveSpray. The spray voltage
was set at 2.2kV and the heated capillary at 200°C. The
LTQ-Orbitrap-XL (ThermoFisherScientific) was operated
in data-dependent mode with dynamic exclusion in which
one cycle of experiments consisted of a full-MS in the
Orbitrap (300-2000 m/z) survey scan in profile mode,
resolution 30,000, and five subsequent MS/MS scans
in the LTQ of the most intense peaks in centroid mode
using collision-induced dissociation with the collision gas
(helium) and normalized collision energy value set at 35%.
Proteins were identified and quantified from spectral data
using Integrated Proteomics Pipeline (IP2) version 1.01
software developed by Integrated Proteomics Applications,
Inc. (http://www.integratedproteomics.com/). Files from
each sample lane were searched against the forward and
reverse Uniprot human database (UniProt release 2013_01
with 20,226 reviewed entries) for partially tryptic peptides
allowing one missed cleavage, and possible modification
of oxidized methionine (15.99492 Da) and heavy arginine
(6.0201 Da) and heavy lysine (8.0142 Da). IP2 uses the
Sequest 2010 (06_10_13_1836) search engine. Mass
tolerances were set at +/- 50 ppm for MS and +/- 1.5 Da
for MS/MS. Data were filtered based on a 1% protein

Super-SILAC standard and proteomics
Unlabeled primary cell lysates were mixed with the
super-SILAC standard in a 1:1 ratio by protein content, as
determined by BCA assay. All samples were desalted and
buffer exchanged to Tris/HCl buffer using Micro bio-spin
6 columns (Bio-Rad, Hercules, CA). Protein concentration
was determined by BCA assay and aliquots containing
80ug of total protein per sample run (up to 240ug for
triplicate analysis) were dried by vacuum centrifugation.
Protein pellets were resuspended in XT sample buffer
containing Criterion XT reducing agent and denatured at
www.impactjournals.com/oncotarget
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false discovery rate and two unique peptides. All the
bands from each lane were \summed in the analysis.
Census software version 1.77, built into the IP2 platform,
was used to determine the ratios of unlabeled and labeled
peptide pairs using an extracted chromatogram approach.
The distribution of ratios was plotted and correction
factors applied to adjust for error in sample mixing. Data
were checked for validity by using regression correlation
better than 0.5 for each peptide pair. Peptide ratios were
averaged to yield the protein ratio with standard deviation.

by 98˚C for 20 sec, 65˚C for 20 sec, 72˚C for 30 sec for
34 cycles) using a forward primer that bound to shared
PKM1/2 exon 8 and a reverse primer that bound to
shared PKM1/2 exon 11 sequences [15]. The 442 bp PCR
products representing both PKM1 and PKM2 transcripts
were then digested with PstI and electrophoresed, after
which the 442 bp (uncut PKM1-specific amplicon) and
246 bp and 196 bp (PstI-cleaved PKM2-specific amplicon)
products were quantitated (Image-J software). Shamdigested PCR products were used as a control for the PCR
amplification while PstI-digested amplification products
derived using a PKM2 cDNA template were used as a
control for restriction enzyme digestion

Western blot
Protein lysates from MB primary cultures and frozen
operative tissue were prepared in lysis buffer (50 mM
HEPES, pH7.0, 150 mM NaCl, 2% SDS, 1 mM EDTA)
supplemented with protease and phosphatase inhibitors
(Roche). Proteins were separated on 4–20% Bis-Tris
gradient polyacrylamide gels (Invitrogen) and transferred
onto Immuno-Blot nitrocellulose membranes (BioRad Laboratories). Membranes were then incubated in
blocking buffer (1X TBS containing 5% milk and 0.05%
Tween-20, 1 hour), probed overnight with antibodies
specific for HNRNPA2/B1 (Cell Signaling, 1:1000),
HNRNPA1 (4B10; Santa Cruz; 1:2000), HNRNPC1/C2
(4F4; Santa Cruz; 1:5000), cMYC (9E10; Santa Cruz;
1:500) and actin (Sigma; 1:2000).

Network analysis for protein-protein interactions

Quantitative RT-PCR

Genome-wide expression analysis

Total RNA was isolated from samples
(Qiagen RNeasy Kit), treated with DNase I, reverse
transcribed (Superscript II Reverse Transcriptase
Kit, Invitrogen) and amplified (initial denaturing
of 95˚C for 3 min followed by 40 cycles at 95˚C
for 15 sec, 60˚C for 15 sec, and 72˚C for 30 sec) in
triplicate using primers designed to bind to PKM1specific exon 9 (F-ACCGCAAGCTGTTTGAAGAA
and R-TCCATGAGGTCTGTGGAGTG) or PKM2specific exon 10 (F-GAGGCCTCCTTCAAGTGCT
and R-CCAGACTTGGTGAGGACGAT), sequences,
respectively as previously described [26]. The mean Ct
values for each set of amplifications were determined,
after which the mean Ct value from triplicate qPCR
reactions using primers for the housekeeping gene Actin
were subtracted to derive a ΔCt value. Relative mRNA
expression was expressed as 2ΔCt.

Previously published microarray expression
and copy-number data3 were obtained from the Gene
Expression Omnibus (GEO; GSE37385 and GSE37382).
The expression data were obtained using the GEOImporter
module in GenePattern. Z scores of gene expression values
of genes within samples were calculated. The genes were
mapped to ensemble identifiers and searched against the
STRING database version 9.1 [13] to identify enriched
interactions.

The Uniprot identifiers of our highly increased
proteins in MYC-amplified tumors (3-fold and higher;
p-value with FDR correction < 0.01) were mapped to the
Ensemble protein identifiers, and then searched against
the STRING database version 9.1 [13] for protein-protein
interactions. Only interactions between the proteins
belonging to our MYC-amplification dataset were selected.
STRING defines a metric called “confidence score” to
define interaction confidence; we fetched all interactions
for our acetylation dataset which had a confidence score ≥
0.7 (high confidence).

Oxygen deprivation
Tumor cells were seeded in triplicate in 24 well
plates (Corning Costar, Sigma Aldrich, St. Louis, MO) in
appropriate medium (blank wells contained only media
without cells). The normoxia set of plates were placed
in an aerobic incubator (atmospheric) and the hypoxic/
anoxic set were placed in a ProOx110/ProCo2/C-Chamber
(Biospherix, Japan), which was equilibrated to 37˚C in
a humidified atmosphere of 5% CO2 and 0.1% O2 . At
the appropriate time, the cells were removed from the
incubator and equal volumes of CellTiter-Glo® (Promega,
Madison, WI) added to each culture and mixed for 2 min
at room temperature as described per protocol. After

PKM splicing assay
The PKM splicing assay used was conducted as
previously described [15, 26]. Briefly, RNA isolated from
normal or tumor samples (fixed or frozen) was reverse
transcribed then amplified (98 ˚C for 3 min followed
www.impactjournals.com/oncotarget

10

Oncotarget

allowing 10 min to stabilize the luminescent signal, 200µl
of each of the lysates (including replicates) were placed
in opaque-walled 96-well plates and the luminescence
recorded (FLUOstar optima, BMG labtech, Ortenberg,
Germany).

UL1TR000075 from the NIH National Center for
Advancing Translational Sciences. Its contents are solely
the responsibility of the authors and do not necessarily
represent the official views of the National Center
for Advancing Translational Sciences or the National
Institutes of Health.

Metabolite measurements

Editorial note

The NADP/NADPH-GloTM assay (Promega,
Madison, WI) was used to detect total oxidized and
reduced nicotinamide adenine dinucleotide phosphates.
The ROS-GloTM H2O2 assay (Promega, Madison, WI) was
used to measure the level of hydrogen peroxide (H2O2)
in culture. All assays were performed as directed in the
protocol. Briefly, for NADP/NADPH measurements,
tumor cells were seeded at the same concentration (104
per well) in triplicate in 24 well plates for 6 hours prior to
the addition of an equal volume of the NADP/NADPHGlo TM detection reagent to each well. The luminescence
is read after incubation with the detection reagent for 60
min at room temperature. For H2O2 measurements, tumor
cells were seeded at the same concentration (104 per
well) in triplicate in 24 well plates for 24 hours (aerobic
incubator). 25µM of the H2O2 substrate was added for the
last 6 hours of incubation and 50µl of media samples per
well were removed and mixed with detection solution
(50µl). Luminescence was measured after incubation with
the detection solution for 20 minutes at room temperature.

This paper has been accepted based in part on peerreview conducted by another journal and the authors’
response and revisions as well as expedited peer-review
in Oncotarget.
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